SANTA CRUZ BIOTECHNOLOGY, INC.

CML66 (W-19): sc-50563



BACKGROUND

The NUDCD1 gene encodes the 583 amino acid CML66 protein which demonstrates expression in a variety of solid tumor cell lines and leukemias. Expression of CML66 in normal tissues is restricted to testis and heart. The CML66 antibody is found in sera of 18-38% of patients with lung cancer, melanoma or prostate cancer. These findings indicate that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy. A short isoform of CML66, designated CML66-S, is a product of alternative splicing. CML66-S has the same C-terminus as full-length CML66 (also designated CML66-L), but has a unique N-terminus. CML66-S shows predominant expression in testis, and is also expressed in very low levels in tumor cells, while CML66 is expressed in tumor cells and testis.

REFERENCES

- Yang, X.F., et al. 2001. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA 98: 7492-7497.
- You, Q., et al. 2004. Cloning, prokaryotic expression of CML66 and preparation of its polyclonal antibody. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19: 582-584.
- Yan, Y., et al. 2004. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J. Immunol. 172: 651-660.
- Wu, C.J., et al. 2005. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin. Cancer Res. 11: 4504-4511.

CHROMOSOMAL LOCATION

Genetic locus: NUDCD1 (human) mapping to 8q23.1; Nudcd1 (mouse) mapping to 15 B3.2.

SOURCE

CML66 (W-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of CML66 of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-50563 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

APPLICATIONS

CML66 (W-19) is recommended for detection of CML66 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

CML66 (W-19) is also recommended for detection of CML66 in additional species, including equine, canine and bovine.

Suitable for use as control antibody for CML66 siRNA (h): sc-60417, CML66 siRNA (m): sc-60418, CML66 shRNA Plasmid (h): sc-60417-SH, CML66 shRNA Plasmid (m): sc-60418-SH, CML66 shRNA (h) Lentiviral Particles: sc-60417-V and CML66 shRNA (m) Lentiviral Particles: sc-60418-V.

Molecular Weight of CML66: 66 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.